Eli Lilly CEO still believes in that $5B budget for R&D

Eli Lilly ($LLY) CEO John Lechleiter says he's standing by his plans to invest big money into R&D, rather than cutting expenses to prepare for new generic competition. Lechleiter tells The Wall Street Journal that he sees "the light at the end of the tunnel," but if pipeline failures continue, then cuts would have to follow. Report

Suggested Articles

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.

FDA advisors will question the clinical data and manufacturing for Mesoblast's Ryoncil, a cell therapy for pediatric acute graft vs. host disease.